Articles tagged with Lung Cancer
Research highlights the development of next-generation CAR T-cells and immune profiling to overcome tumor resistance. SU2C presents work on cancer interception, convergence, and clinical trials for pancreatic, pediatric, brain, colorectal, lung, ovarian, and breast cancers.
Researchers have developed a mini-protein MYC inhibitor that effectively treats non-small cell lung cancer, exhibiting minimal side effects. The therapy works by targeting the MYC oncogene, leading to reduced tumor growth and improved patient outcomes.
Francoise Mornex, a renowned French oncologist, has been awarded the prestigious Heine H. Hansen Award for her groundbreaking contributions to the treatment of lung cancer. Her research focuses on combined chemoradiation strategies, multimodality treatment, and innovative radiotherapy techniques.
Researchers have developed a new method to detect small fragments of cancerous genetic material in blood samples from lung cancer patients. The method, called liquid biopsy, uses ultra-deep next-generation sequencing and machine learning to identify genetic variants driving the cancer or making it resistant to treatment.
Researchers found that ZEB1 forces KRAS-driven lung cancer cells to switch from stable to mobile, resistant mesenchymal cells, making them less responsive to MEK inhibitors. A combination of an HDAC inhibitor and a MEK inhibitor reversed this transition and restored vulnerability to targeted therapy.
A VA study examined the use of video-assisted thoracoscopic lung resection in patients with known or suspected lung cancer from 2002 to 2015. The proportion of this minimally invasive procedure increased significantly over time, but its adoption varied by VA region.
Researchers at the University of Pittsburgh and UPMC Hillman Cancer Center have developed an AI model that can accurately identify benign nodules in low-dose CT scans, reducing false positives by up to 30%. This means patients with benign nodules won't need additional testing or biopsies, streamlining their care.
Researchers at University of Tsukuba uncover how stratifin causes lung adenocarcinoma to emerge, identifying two drugs with other clinical uses that could be applied effectively in this disease. The study's findings raise hopes for more powerful treatment tools and value drug repositioning as a potential solution.
A team of researchers led by James DeGregori will identify lung tissue characteristics that enable cancer cell growth, aiming to predict cancer risk and develop interventions. The study aims to modulate the lung environment to reduce cancer risk, rather than targeting cancer cells alone.
Researchers found that sarcopenia is significantly associated with poor response to cancer treatments, including PD-1 inhibitors. Increasing muscle mass prior to treatment may predict treatment effectiveness and improve long-term outcomes for patients with advanced non-small cell lung cancer.
A team of researchers at Dartmouth's Norris Cotton Cancer Center has developed a deep neural network to classify different types of lung adenocarcinoma on histopathology slides. The model achieved high accuracy comparable to that of pathologists, showing great potential for assisting in prognosis and treatment.
Researchers found that lung cancer cells acquire resistance to molecular-targeted drugs by transforming epithelial characteristics into mesenchymal ones, leading to reduced miR-200c expression. Sequential treatment with an HDAC inhibitor and a next generation molecular-targeted drug overcomes this resistance, offering new potential for...
Scientists at Kanazawa University found that AXL protein is responsible for resistance to osimertinib, a tyrosine kinase inhibitor used to treat EGFR-mutated lung cancer. Inhibiting AXL expression can prevent tumor regrowth and improve treatment outcomes.
Researchers at Osaka University have found a correlation between T cell activity in lung tumors and blood, predicting the efficacy of immune system-targeting therapy. This breakthrough enables non-invasive diagnosis and personalized treatment planning for lung cancer patients.
Researchers discovered that COPD patients often confuse early signs of lung cancer with their existing condition, leading to delayed diagnosis. The study emphasizes the need for healthcare professionals to educate patients about their increased risk and be more vigilant when symptoms change.
A research team at the University of Louisville discovered that SA-4-1BBL boosts CD8+ and CD4+ T cells to target tumors for destruction. The molecule protects healthy mice from various cancer types when exposed to tumor cells, showing promise in cancer immunoprevention.
The black-white cancer mortality gap has closed considerably over the past several decades, with faster declines among black Americans. The disparities have narrowed for lung, prostate, and colorectal cancers, and have stabilized since 2010 for breast cancer.
Researchers have found evidence of pre-cancerous lung tumours in mice using a blood-based test, suggesting a potential early detection method for lung cancer. The study used mice with a mutation in the KRAS gene to model the disease and found that circulating DNA levels correlated with tumour size.
A University of Colorado study shows that low-molecular weight PAHs, commonly found in secondhand smoke and environmental exposures, can cause cancer-promoting changes in lung cells within 30 minutes.
A study of 2,766 physicians found that those receiving payments from a cancer drug's manufacturer were more likely to prescribe the drug for certain types of cancer, including kidney and lung cancer. Financial relationships between physicians and drug companies can influence prescribing practices.
Researchers from the University of Exeter have developed a new graphene biosensor that can detect molecules of common lung cancer biomarkers. The device has the potential to revolutionize existing electronic nose devices and provide an early-stage lung cancer diagnosis through a convenient and reusable breath test.
Researchers found that lung tumors exploit altered bacterial populations to create an inflammatory environment that promotes their survival. Treating mice with antibiotics or blocking immune cells significantly reduced tumor size.
A new study found that complication rates following invasive lung cancer diagnostic tests are twice as high in the community setting compared to clinical trials, with associated downstream costs of $6,320 to $56,845 on average. The researchers emphasize the need for sharing risks with patients considering lung cancer screening.
Researchers at Osaka University have identified Semaphorin 7a as a protein involved in treatment resistance in lung cancer cells with common EGFR mutations. High levels of Semaphorin 7a inhibit apoptosis, making it harder for cancerous cells to be eradicated.
The US cancer death rate has declined by 27% since 1991, primarily due to reductions in smoking and advances in early detection and treatment. Despite this progress, socioeconomic inequalities have widened, with poorer counties experiencing a disproportionate burden of preventable cancers.
A new study found that patients with stage IV ALK-positive lung cancer have a median overall survival of 6.8 years, significantly higher than the 2 percent five-year survival rate for all NSCLC patients. This optimistic outlook is attributed to targeted therapies and careful surveillance.
A large registry-linkage study found a 13-fold increased risk of lung cancer in single lung transplant recipients' native lungs compared to the general population. Longtime since transplantation and prior smoking are associated with higher lung cancer risk.
The IASLC has launched a pilot project to develop an innovative technique for improving early lung cancer detection through shared computed tomography images. The project aims to create a globally-accessible environment for analyzing large collections of quality-controlled CT lung cancer images and associated biomedical data.
Researchers at Case Western Reserve University have developed a novel computerized approach to detect lung cancer using routine CAT scans. The method analyzes patterns of heterogeneity within and outside the tumor, distinguishing benign from malignant nodules with high accuracy.
A new study published in Molecular Therapy Oncolytics found that combining chemotherapy with CRISPR-Cas9 can stop tumor growth and reduce existing tumor volume in both tissue culture and mouse models. The CRISPR application disables the NRF2 gene, which helps lung cancer tumors develop resistance to chemotherapies.
A new study published in BMJ found that primary care doctors need to work six more hours a day to provide recommended preventive care, including colonoscopy and lung cancer screening. The simulation model also reveals that this would lead to 17 out of every 100 doctors taking early retirement each year.
The MYSTIC trial found that first line immunotherapy combination with durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer. However, a subgroup of patients with high tumour mutational burden showed improved overall survival with the combination treatment.
A study of over 280,000 people found a significant association between work stress and increased risk of colorectal and esophagus cancers. However, no link was observed for prostate, breast, or ovarian cancers, with the relationship varying by region.
Researchers predict a decline in cancer death rates in Australasian countries and Russia in 2018. However, the largest number of deaths are predicted for Russia, mainly due to high rates among men who still smoke. The study highlights the need for urgent measures on tobacco control in Russia.
Researchers identified a key enzyme linked to therapy resistance in EGFR-mutant non-small cell lung cancer. The study found that inhibiting this enzyme can lead to tumor regression and improved treatment outcomes.
A new epigenetic therapy targeting enzyme G9a boosts cancer stem cells that drive adenocarcinoma in mice, but also identifies a strategy reducing these cells. Researchers now explore demethylase inhibitors as potential therapeutic drugs to curb lung cancer progression.
Scientists at UCLA have identified sodium glucose transporter 2 (SGLT2) as a key mechanism in lung cancer cell growth, which could lead to earlier diagnosis and treatment. The study found that SGLT2 is predominantly used by lung cancer cells to transport glucose, even in pre-malignant lesions.
The combination therapy of NIR178 and spartalizumab has shown activity in non-small cell lung cancer patients, with two complete responses and 14 patients experiencing stable disease. The treatment was well-tolerated, with most side effects being mild to moderate.
Researchers at the Salk Institute found that late-stage cancers trigger AMPK's cellular recycling signal to cannibalize cell pieces, supplying large lung tumors with nutrients. Blocking AMPK in some conditions may stop advanced tumor growth.
Researchers have developed a new strategy against HER2-driven lung cancers using tarloxotinib, a potent HER2/EGFR inhibitor that is more active in low-oxygen conditions than existing therapies. This innovative approach has shown significant promise in treating patients with HER2 lung cancer.
Research suggests excessive sitting increases risk of premature death and chronic diseases by 10-20%, but this risk pales in comparison to smoking's significant harm. Smoking carries a substantially higher risk of cancer, cardiovascular disease, and lung cancer compared to sitting.
Researchers found that targeting tumor sites with radiation or surgery after initial treatment can significantly improve overall survival time for patients. Progression-free survival and toxicity data also showed benefits, with median overall survival times of up to 41.2 months.
The IASLC affirms the strength of evidence supporting lung cancer screening, reducing mortality by 26-61% in high-risk populations. The organization recommends implementing global lung cancer screening programs, incorporating multidisciplinary teams and best-practice smoking cessation.
A study found that angiotensin converting enzyme inhibitor (ACEI) drugs increase the risk of lung cancer by 14% compared to angiotensin receptor blockers (ARBs). The risk is highest among patients using ACEIs for over five years, particularly those who use them for more than 10 years.
A randomized study shows erlotinib improves progression-free survival and tumor response rate compared to gemcitabine plus cisplatin in stage IIIA-N2 EGFR-mutated NSCLC. Median progression-free survival was significantly longer with erlotinib at 21·5 months versus 11.9 months with chemotherapy.
Studies show that exercise can significantly reduce fatigue and improve well-being in patients with advanced lung cancer, improving symptom scores by approximately 10% during chemotherapy. Gentle aerobic exercise and strength training are recommended as part of treating the disease.
Researchers at Huntsman Cancer Institute discovered that different types of lung tumors recruit distinct immune cells, which can help or hinder tumor growth. The study found that high levels of neutrophils are associated with a bad response to immunotherapy, suggesting them as a potential target for new treatments.
Researchers found that a blood test identified significantly more treatable mutations in non-small cell lung cancer (NSCLC) than a tissue biopsy alone. Patients with actionable mutations detected by the liquid biopsy responded favorably to targeted therapies, achieving high clinical response rates.
A recent study published in Cancer Prevention Research reveals that California's long-term tobacco control efforts have led to a 28% decrease in lung cancer deaths compared to the rest of the country. The state's approach has been particularly effective in discouraging young people from starting to smoke, with a 39% lower initiation ra...
Researchers found no clear evidence that statins benefit patients with non-Cardiovascular Disease (CVD) conditions, except for preventing deaths from kidney disease. Statins may also slow cancer progression, but further investigation is needed.
Researchers at UCLA will use a new liquid biopsy tool to test individuals at risk of lung cancer, with the goal of detecting the disease earlier. The technology aims to differentiate between cancerous and benign lung lesions, reducing unnecessary procedures and improving patient outcomes.
A new technology called EFIRM has been developed to detect two cancer-linked mutations in blood or saliva samples from patients with early-stage lung cancer. The platform shows promise in identifying stages 1 and 2 NSCLC when surgical resection is still possible, offering a potential cure.
A study found that despite a well-designed low-dose computed tomography (LDCT) screening program, only 77.6% of eligible veterans underwent annual repeat scans. This highlights the need for improved adherence to lung cancer screening to maximize mortality benefits and cost-efficacy.
Researchers found that more frequent surveillance imaging was not associated with improved overall survival for NSCLC patients. Annual surveillance is recommended as a standard practice, offering no additional benefits over six-monthly visits.
The report reveals a high burden of prostate and colorectal cancers among Hispanic men in Puerto Rico, contrasting with lower rates among non-Hispanic whites. The study emphasizes the need for culturally tailored strategies to address these disparities and promote healthy lifestyle behaviors.
Scientists at UNIGE discovered that resveratrol, a molecule in grape skin and seeds, can prevent lung cancer in mice treated with a nasal formulation. The study showed a 45% decrease in tumor load and a higher concentration of resveratrol in the lungs after nasal administration.
Moffitt researchers used a new technique to identify a previously unknown mechanism of midostaurin in lung cancer. Combining functional proteomics with deep network analysis led to the discovery of TBK1, PDPK1, and AURKA as protein targets for midostaurin, resulting in a more effective combination therapy.
A new clinical trial has found that durvalumab improved progression-free survival by 17.2 months compared to placebo in patients with stage 3 non-small cell lung cancer. Overall survival rates also increased, with 66.3% of patients surviving at two years, compared to 55.6% on placebo.
The ALTA-1 trial found brigatinib to be a first-line treatment option for advanced ALK-positive non-small cell lung cancer, with a 51% reduction in progression or death risk compared to crizotinib. Patients treated with brigatinib also showed improved response rates and longer progression-free survival.
Phase 1 and phase 2 clinical trials of entrectinib in ROS1-positive non-small cell lung cancer demonstrated a response rate of 77.4 percent and median duration of response of 24.6 months. Entrectinib also showed competitive results in patients with brain metastases and poor prognosis